Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BMS-247550 Bristol-Myers Squibb/GBF.

Nancy Lin1, Katherine Brakora, Michael Seiden

  • 1Division of Hematology and Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|August 7, 2003
PubMed
Summary

Bristol-Myers Squibb is developing BMS-247550, an epothilone cancer treatment. Phase II trials for various tumors, including lung and breast cancer, were initiated, with potential commercialization in 2004.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonist.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.

JCO precision oncology·2026
Same author

Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

JCO clinical cancer informatics·2025
Same author

Case Report: Unlocking opportunities in HER2-targeted antibody-drug conjugates for bulky leptomeningeal metastatic breast cancer.

Frontiers in oncology·2025

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epothilones are a class of microtubule-stabilizing agents investigated for cancer therapy.
  • BMS-247550 is an epothilone derivative developed by Bristol-Myers Squibb and the German Research Centre for Biotechnology.

Purpose of the Study:

  • To evaluate the efficacy and safety of BMS-247550 in patients with various types of cancer.
  • To advance BMS-247550 through clinical trials for potential cancer treatment.

Main Methods:

  • Phase I and Phase II clinical trials were conducted in adult and pediatric populations.
  • Studies included patients with non-small-cell lung cancer and breast cancer.

Main Results:

  • BMS-247550 successfully completed Phase I trials by September 2000.
  • Phase II trials were initiated in February 2001 for various tumor types.
  • Phase I trials in children began by April 2002.

Conclusions:

  • BMS-247550 demonstrated progress through early-stage clinical trials for cancer treatment.
  • The drug was anticipated for regulatory filing in 2003 and commercialization in 2004.

Related Experiment Videos